New COVID-19 antibody enters first human safety trial
NCT ID NCT06965751
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a new drug called PDI204, an antibody that targets the COVID-19 virus, is safe and tolerable in healthy adults. 32 participants will receive a single dose of PDI204 or a placebo and be monitored for side effects and how the drug behaves in the body. The study is a first step to see if PDI204 could eventually be used to treat or prevent COVID-19.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PDI204 (a monoclonal antibody targeting the SARS-CoV-2 spike protein)
- What this could lead to
- If successful, this could lead to a new treatment or preventive option for COVID-19.
- What could go wrong
- This is a very early Phase 1 trial with only 32 healthy people, so it is too soon to know if PDI204 works or is safe for patients. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone qigong program heal the mental toll of COVID-19?
- AI analyzes 100,000 COVID-19 cases to predict who gets worst outcomes
- New ibuzatrelvir tablet put to the test in healthy volunteers
- New vaccine aims to shield leukemia patients from COVID-19
- Cancer Patients' pandemic struggles revealed in new study
- Survey reveals how pandemic reshaped lung care